Loading...
•
Jun 30, 2025
Alcon Q2 2025 Earnings Report
Alcon reported its second-quarter 2025 financial results, including sales of $2.6 billion, diluted EPS of $0.35, and core diluted EPS of $0.76. The company also launched Tryptyr and announced the acquisition of STAAR Surgical.
Key Takeaways
Alcon delivered solid second-quarter 2025 results with sales reaching $2.6 billion, a 4% increase on a reported basis. Diluted EPS was $0.35, and core diluted EPS stood at $0.76. The company generated strong free cash flow in the first half of the year and returned $287 million to shareholders. Strategic moves included the launch of Tryptyr for dry eye disease and the announced acquisition of STAAR Surgical to expand its myopia correction portfolio.
Second-quarter 2025 sales reached $2.6 billion, marking a 4% increase on a reported basis compared to the second quarter of 2024.
Diluted EPS for the second quarter was $0.35, while core diluted EPS was $0.76.
Alcon generated $681 million in free cash flow during the first half of 2025 and returned $287 million to shareholders through share repurchases and dividends.
The company expanded its product portfolio and market presence with the launch of Tryptyr for dry eye disease and the announced acquisition of STAAR Surgical, aiming to address the growing myopia epidemic.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Alcon updated its 2025 outlook, adjusting net sales and core operating margin expectations while maintaining core diluted EPS guidance. The outlook assumes low-single digit market growth and anticipates fully offsetting a $100 million gross tariff impact through operational actions and foreign exchange.
Positive Outlook
- Core diluted EPS guidance maintained at $3.05 to $3.15.
- Anticipates fully offsetting a full-year gross tariff impact of approximately $100 million through operational actions and foreign exchange.
- Aggregated markets are expected to grow approximately low-single digits.
- Exchange rates as of the end of July are assumed to prevail through year-end, providing stability.
- The company expects to manage its weighted-averaged diluted shares at approximately 498.8 million.
Challenges Ahead
- Net sales outlook updated to $10.3 billion to $10.4 billion, a reduction from the previous guidance of $10.4 billion to $10.5 billion.
- Change versus prior year (constant currency) for net sales updated to +4% to +5%, down from +6% to +7%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...